Zentalis
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
10275 Science Center Dr Ste 200, San Die...Phone Number
(212) 433-3791Website
www.zentalis.comRevenue
$26.9 MillionStock Symbol
ZNTLIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Zentalis
Zentalis Pharmaceuticals is a biopharmaceutical company focused on developing differentiated therapeutics targeting cancer pathways. Zentalis was founded in 2014 and is headquartered in New York City, New York.Explore more
Zentalis Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zentalis your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Zentalis is spiking on competitors!
Product Launch: Get notified when Zentalis launches new products
Click to see if Zentalis had a recent Job posting/layoffs
Check if Zentalis has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Zentalis, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Zentalis
Earning: See what the market has to say on Zentalis recently announced quarterly report
Funding: Get notified immidiatlly once Zentalis has new funding data
Recommended Actions
Reach out to Masked Content who joined Zentalis as Masked Content
Find 3 more new buyers
Compare Similar Companies to Zentalis
Compare insights from companies similar to Zentalis, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Zentalis is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zentalis is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zentalis.
Zentalis financials insights
Gather financial insights about Zentalis, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$165M
Series A
$20M
2021
Share Placement
$150.4M
Series B
$75M
Zentalis Tech Stack
A closer look at the technologies used by Zentalis
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Project
Zentalis News & Media
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on June 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 191,000 shares of the Company’s common stock to two (2) newlyZentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy
SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced the appointments of Shannon Campbell to its Board of Directors and Sarah Kelly as the Company’s Senior Vice President of Commercial Strategy. These appointments reflect Zentalis’ continued commitment to deveZentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that data from Part 1 of the Phase 1b MUIR trial will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29 – June 2, 2026, in Chicago, Illinois. The poster,Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences:
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Zentalis
Sign Up For FreeTo access detailed company insights
Zentalis Pharmaceuticals is a biopharmaceutical company focused on developing differentiated therapeutics targeting cancer pathways. Zentalis was founded in 2014 and is headquartered in New York City, New York.... Read More
